留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

脂微球载药系统的研究进展

章秀丽,  马月琴,  李刚

downloadPDF
文章导航 > 药学实践与服务  > 2014 >  32(6): 409-411,459
章秀丽, 马月琴, 李刚. 脂微球载药系统的研究进展[J]. 药学实践与服务, 2014, 32(6): 409-411,459. doi: 10.3969/j.issn.1006-0111.2014.06.003
引用本文: 章秀丽, 马月琴, 李刚. 脂微球载药系统的研究进展[J]. 药学实践与服务, 2014, 32(6): 409-411,459. doi: 10.3969/j.issn.1006-0111.2014.06.003
shu
ZHANG Xiuli, MA Yueqin, LI Gang. Research development of lipid microsphere delivery system[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 409-411,459. doi: 10.3969/j.issn.1006-0111.2014.06.003
Citation: ZHANG Xiuli, MA Yueqin, LI Gang. Research development of lipid microsphere delivery system[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 409-411,459. doi: 10.3969/j.issn.1006-0111.2014.06.003
shu

脂微球载药系统的研究进展

doi: 10.3969/j.issn.1006-0111.2014.06.003

  • 解放军94医院药械科, 江西 南昌 330002

基金项目: 江西省自然科学基金项目(20122BAB215038).

Research development of lipid microsphere delivery system

  • Department of Pharmacy, No. 94 Hospital of PLA, Nanchang 330002, China

  • 摘要: 脂微球递药系统是药剂学研究的热点,从脂微球载药系统的形成机制、构建方法及关键影响因素等方面进行综述,介绍该领域研究的进展和一些新发现,以促进脂微球作为药物载体的开发和应用。
    Abstract: Lipid microsphere drug delivery system is a hot issue in pharmceutics studies. In this paper, the mechanism, preparation method and the key influence factors of lipid microsphere drug delivery system were reviewed respectively. Some new discovery and development were introduced in order to enhance the development and application of lipid microsphere drug delivery system as a drug delivery tool.
  • [1] Liu ZZ, Feng YY, Zhang LL, et al. Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution[J]. Cancer Chemother Pharmacol, 2013, 71(5): 1131-1139.
    [2] McClements DJ. Advances in fabrication of emulsions with enhanced functionality using structural design principles[J]. Curr Opin Colloid Interf Sci, 2012, 17(5): 235-245.
    [3] Groves MJ. The redistribution of bulk aqueous phase phospholipids during thermal stressing of phospholipid-stabilized emulsions[J]. Pharm Pharmacol, 1993, 45(7): 592.
    [4] Morais JM, Burgess DJ. Long acting injections and implants: micro-and nano-emulsions (controlled release parenteral drug delivery systems)[M].London: Springer, 2012: 221-238.
    [5] Yue PF, Lu XY, Liao MX, et al. The effect of oil components and homogenization conditions on the physicochemical properties of zedoary turmeric oil submicron emulsions[J]. J Dispers Sci Technol, 2010, 31(11):1535-1540.
    [6] Patel R, Joshi J. An overview on nanoemulsion: a novel approach[J]. Int J Pharml Sci Res, 2012, 3(12): 4640-4650.
    [7] Bague S, Philips B, Rabinovich-Guilatt L, et al. Ophthalmic oil-in-water type emulsion with stable zeta potential[P].USA WO2006050838 A2, 2005-10-10.
    [8] Akkar A, Muller RH. Intravenous itraconazole emulsions produced by SolEmuls technology[J]. Eur J Pharm Biopharm, 2003, 56(1): 29-36.
    [9] Müller RH, Schmidt S, Buttle I, et al. SolEmuls®-novel technology for the formulation of i.v. emulsions with poorly soluble drugs[J]. Int J Pharm, 2004, 269(2): 293-302.
    [10] Yue PF, Li FQ, Liao MX, et al. Process optimization, characterization, and release study in vitro of an intravenous puerarin lipid micropheres loaded with the phospholipid complex[J]. J Dispers Sci Technol, 2011, 32(1): 1-10.
    [11] Yue PF, Zheng Q, Wu B, et al. Application of plackett-burman design and box-behnken design to achieve process optimization for geniposide submicron emulsion[J]. J Dispers Sci Technol, 2012, 33(2): 213-222.
    [12] Ma YQ, Li G, Xu JH, et al. Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid[J]. Pharm Dev Technol,2014,19(3):363-372.
    [13] Gulati Neha, Gupta Himanshu. Parenteral drug delivery: a review[J]. Recent Patent Drug Deliv Form, 2011, 5(2): 133-145.
    [14] Yamamura K, Nakao M, Yano K, et al. Stability of forskolin in lipid emulsions and oil/water partition coefficients[J]. Chem Pharm Bull,1991, 39(4):1032-1034.
    [15] Bhalerao AV, Singh SS. In situ gelling ophthalmic drug delivery system for glaucoma[J]. Int J Pharm Biosci, 2011, 2(2): 7-14.
    [16] Patel Y, Poddar A, Sawant K. Formulation and characterization of Cefuroxime Axetil nanoemulsion for improved bioavailability[J]. J Pharm Bioallied Sci, 2012, 4(1): S4-S5.
    [17] Ammar H, Salama H, Ghorab M, et al. Nanoemulsion as a potential ophthalmic drug delivery system for Dorzolamide hydrochloride[J]. AAPS Pharm Sci Tech, 2009, 10(3): 808-819.
    [18] Gan L, Wang J, Jiang M, et al.Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers[J]. Drug Discov Today, 2013, 18(5-6): 290-297.
    [19] Lu Y, Qi J, Wu W. Absorption, disposition and pharmacokinetics of nanoemulsions[J]. Curr Drug Metab,2012, 13(4): 418-428.
    [20] Sultana Y, Maurya DP, Iqbal Z,et al. Nanotechnology in ocular delivery: current and future directions[J]. Drugs Today, 2011, 47(6): 441-455.
    [21] Zhang N, Zhang Q, Chu T, et al. Formulation optimization of prostaglandin E1-loaded lipid emulsion: enhanced stability and reduced biodegradation[J]. Pharm Dev Tech, 2013, 18(4): 804-812.
    [22] GaoY, Xu PF, Chen LL, Li YP. Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect[J]. Int J Pharm, 2010, 387(1-2): 263-271.
    [23] Ueki R, Tanimoto M, Tatara T, et al. Emulsion of flurbiprofen axetil reduces propofol injection pain due to a decrease in free propofol concentration[J]. J Anesth, 2007, 21 (3): 325-329.
    [24] Shen J, Gan L, Zhu C, et al. Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect[J]. Int J Pharm, 2011, 412(1-2):115-122.
  • [1] 毛智毅, 王筱燕, 陈晓颖, 汤逸斐.  度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
    [2] 杨嘉宁, 赵一颖, 肖伟.  七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
    [3] 顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩.  侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
    [4] 王雪莲, 郑斯莉, 李志勇, 罗亨宇, 缪朝玉.  全身过表达人METRNL基因小鼠模型的构建与验证 . 药学实践与服务, 2024, 42(5): 198-202, 222. doi: 10.12206/j.issn.2097-2024.202311014
    [5] 张莲卿, 骆岩, 杨提, 姚佳晨, 李文艳.  基于FAERS数据库的艾塞那肽微球不良事件信号挖掘与研究 . 药学实践与服务, 2024, 42(10): 445-450. doi: 10.12206/j.issn.2097-2024.202403057
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  4208
  • HTML全文浏览量:  432
  • PDF下载量:  262
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-05-21
  • 修回日期:  2014-03-17

脂微球载药系统的研究进展

doi: 10.3969/j.issn.1006-0111.2014.06.003
  • 解放军94医院药械科, 江西 南昌 330002
    • 基金项目:  江西省自然科学基金项目(20122BAB215038).
  • 收稿日期: 2013-05-21
  • 修回日期: 2014-03-17

摘要: 脂微球递药系统是药剂学研究的热点,从脂微球载药系统的形成机制、构建方法及关键影响因素等方面进行综述,介绍该领域研究的进展和一些新发现,以促进脂微球作为药物载体的开发和应用。

English Abstract

章秀丽, 马月琴, 李刚. 脂微球载药系统的研究进展[J]. 药学实践与服务, 2014, 32(6): 409-411,459. doi: 10.3969/j.issn.1006-0111.2014.06.003
引用本文: 章秀丽, 马月琴, 李刚. 脂微球载药系统的研究进展[J]. 药学实践与服务, 2014, 32(6): 409-411,459. doi: 10.3969/j.issn.1006-0111.2014.06.003
shu
ZHANG Xiuli, MA Yueqin, LI Gang. Research development of lipid microsphere delivery system[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 409-411,459. doi: 10.3969/j.issn.1006-0111.2014.06.003
Citation: ZHANG Xiuli, MA Yueqin, LI Gang. Research development of lipid microsphere delivery system[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 409-411,459. doi: 10.3969/j.issn.1006-0111.2014.06.003
shu

    全文HTML

参考文献 (24)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计